McClay E F, Mastrangelo M J, Bellet R E, Berd D
Cancer Treat Rep. 1987 May;71(5):465-9.
Twenty-three patients with metastatic melanoma were treated with combination therapy consisting of dacarbazine (220 mg/m2) and cisplatin (25 mg/m2) iv daily for 3 days every 3 weeks, carmustine (150 mg/m2) iv every 6 weeks, and tamoxifen (10 mg) orally twice daily. In 20 evaluable patients, there were no complete responses and ten partial responses. The median remission duration has not yet been reached but exceeds 7 months. Treatment was relatively well tolerated. However, six patients developed deep venous thrombosis, and four of these six suffered pulmonary emboli. Our data support a previous study and suggest that this combination warrants comparison with the active single components in a randomized prospective trial.
23例转移性黑色素瘤患者接受联合治疗，方案为：达卡巴嗪（220mg/m²）和顺铂（25mg/m²）静脉滴注，每日1次，连用3天，每3周重复；卡莫司汀（150mg/m²）静脉滴注，每6周1次；他莫昔芬（10mg）口服，每日2次。20例可评估患者中，无完全缓解，10例部分缓解。中位缓解持续时间尚未达到，但超过7个月。治疗耐受性相对良好。然而，6例患者发生深静脉血栓形成，其中4例并发肺栓塞。我们的数据支持之前的一项研究，并表明该联合方案值得在随机前瞻性试验中与有效的单一成分进行比较。
